Rockefeller Capital Management L.P. Acquires 6,678 Shares of Guardant Health, Inc. $GH

Rockefeller Capital Management L.P. raised its holdings in Guardant Health, Inc. (NASDAQ:GH) by 135.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,618 shares of the company’s stock after buying an additional 6,678 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Guardant Health were worth $1,187,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the fourth quarter valued at approximately $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health during the fourth quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Guardant Health during the 4th quarter valued at $31,000. Elyxium Wealth LLC acquired a new position in Guardant Health during the 4th quarter valued at $35,000. Finally, Parallel Advisors LLC boosted its holdings in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares during the period. 92.60% of the stock is owned by institutional investors.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the completion of the transaction, the director owned 11,183 shares in the company, valued at $1,420,017.34. This trade represents a 47.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 210,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total value of $23,076,900.00. Following the sale, the chief executive officer directly owned 1,886,504 shares in the company, valued at $207,307,924.56. The trade was a 10.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 712,513 shares of company stock valued at $90,921,587. Corporate insiders own 5.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Guardant Health in a research report on Friday, June 5th. They issued a “buy” rating and a $165.00 price target on the stock. Piper Sandler set a $127.00 target price on Guardant Health in a research report on Thursday, May 21st. Wolfe Research started coverage on Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target on the stock. Barclays upped their price target on Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Finally, Sanford C. Bernstein assumed coverage on Guardant Health in a research report on Friday, June 26th. They issued an “outperform” rating and a $175.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $146.18.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $170.77 on Thursday. The firm’s 50-day simple moving average is $116.77 and its 200-day simple moving average is $105.20. Guardant Health, Inc. has a twelve month low of $40.35 and a twelve month high of $172.61. The firm has a market cap of $22.64 billion, a P/E ratio of -50.37 and a beta of 1.59.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.